Brind.
  1. Biomea Fusion reported that its next-generation GLP-1 RA candidate, BMF-650, combined with icovamenib, drove superior glycemic control.

Biomea Fusion presented new clinical data on its BMF-650/icovamenib combination at the ADA conference.

2 reports, 2 independent Updated Jun 6
Gone quiet Reached 2 outlets in its first 24 hours
Reports
2
Developments
2
Repetition
0%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Biomea Fusion presented new clinical data on its BMF-650/icovamenib combination at the ADA conference.

Who's involved

What this event is mainly about
American Diabetes Association

How it developed

Newest first. Tap a step to see who reported it.
  1. Biomea Fusion identified menin as a target for metabolic demand and discussed non-chronic dosing strategies.1 source
  2. New data presented at ADA shows BMF-650/icovamenib promise in T1D/T2D.1 source

Keep exploring

Part of

Biomea Fusion reported that its next-generation GLP-1 RA candidate, BMF-650, combined with icovamenib, drove superior glycemic control. All 1 developments

The entities involved

Coverage

Newest first; wire copies grouped